Advertisement
Pharma/Biotech News
Subscribe to Pharma/Biotech News

The Lead

Baxter's Hemophilia Drug Hits Phase 3 Endpoint

August 22, 2014 4:05 pm | News | Comments

Baxter International Inc. announced positive results from its Phase 3 pivotal clinical trial of BAX 855, an investigational, extended half-life recombinant factor VIII (rFVIII) treatment for hemophilia A. Read more...          

Janssen, ViaCyte Partner on Potential Diabetes Treatment

August 22, 2014 3:55 pm | News | Comments

ViaCyte Inc., a privately held regenerative medicine company announced that it has entered into...

Mylan Launches First Generic Klor-Con Extended-Release Tablets

August 22, 2014 3:46 pm | News | Comments

Mylan Inc. announced that it has launched Potassium Chloride Extended-release Tablets USP, 8 mEq...

Combining Vaccines Boosts Polio Immunity

August 22, 2014 3:11 pm | by Lauran Neergaard, AP Medical Writer | News | Comments

New research suggests a one-two punch could help battle polio in some of the world's most remote...

View Sample

FREE Email Newsletter

Daily news and top headlines for drug research professionals

Antitope, University College London Collaborate on Fully Humanized Antibodies

August 22, 2014 11:06 am | News | Comments

Antitope Ltd. and University College London are pleased to announce that they will collaborate to humanize an anti-LRG1 antibody as part of a MRC-funded translational research and product development program being undertaken by the UCL Institute of Ophthalmology. Read more...

OncoGenex Says Lung Cancer Drug Trial Will Continue

August 22, 2014 11:01 am | News | Comments

OncoGenex Pharmaceuticals announced that the Phase 3 ENSPIRIT trial, evaluating custirsen in the treatment of non-small cell lung cancer, is continuing as planned per the recommendation of the Independent Data Monitoring Committee based upon completion of the first interim futility analysis. Read more...

EMA Accepts Ceftolozane/Tazobactam MAA for Review

August 22, 2014 10:54 am | News | Comments

Cubist Pharmaceuticals announced that the European Medicines Agency has accepted for review the company’s Marketing Authorization Application for its investigational antibiotic ceftolozane/tazobactam for the treatment of complicated urinary tract Infections and complicated intra-abdominal infections. Read more...

Advertisement

Mutated Polio Virus Breaches Vaccine Protection

August 22, 2014 10:48 am | News | Comments

Scientists of the University of Bonn, together with colleagues from Gabon, are reporting alarming findings: a mutated polio virus that was able to resist the vaccine protection to a considerable extent was found in victims of an outbreak in the Congo in 2010. Read more...

Bioethicists Say Ebola Drugs Must be Fairly Distributed, Tested Ethically

August 22, 2014 10:42 am | News | Comments

Researchers and health authorities need to ensure that experimental drugs to treat Ebola are distributed fairly, and in the context of randomized controlled trials in collaboration with local communities and other stakeholders, according to a new Viewpoint, published in The Lancet. Read more...

The Case for Orphan Drugs

August 22, 2014 10:34 am | by Louise Rozik, Editor | Articles | Comments

Neglected by the pharmaceutical industry before the Orphan Drug Act of 1983, rare diseases are now front and center in pharma R&D, with approximately one-third of all new medicines approved by the FDA in the past 5 years having been developed for the treatment of diseases that affect fewer than 200,000 Americans. Read more...

AstraZeneca, Illumina Partner on Gene Sequencing

August 21, 2014 4:12 pm | News | Comments

AstraZeneca announced that it has entered into a collaboration with gene sequencing company, Illumina Inc., to develop its next generation sequencing platform for companion diagnostic tests applicable across AstraZeneca’s oncology portfolio. Read more…

FDA Clears Eliquis for New Use Against Blood Clots

August 21, 2014 3:28 pm | by The Associated Press | News | Comments

Bristol-Myers Squibb and Pfizer said Thursday that federal regulators have expanded approval of their blood thinner Eliquis to treat two types of dangerous blood clots. Read more...                    

Advertisement

Amid ALS Mania, Possible Drug Target Spotted

August 21, 2014 3:02 pm | by Cynthia Fox, Science Editor | Articles | Comments

As, all around them, everyone from Derek Jeter to the Kennedy family was dousing themselves in ice water for the ALS “Ice Bucket Challenge,” Harvard researchers announced last week they may have found an ALS therapy. Read more...      

New Hydrocodone Restrictions to Take Effect

August 21, 2014 1:00 pm | News | Comments

The federal government is finalizing new restrictions on hundreds of medicines containing hydrocodone, the highly addictive painkiller that has grown into the most widely prescribed drug in the U.S. Read more...            

Both American Ebola Patients Discharged from Hospital

August 21, 2014 1:00 pm | by Jeff Martin and Katie Foody | News | Comments

After nearly three weeks of treatment, the two American aid workers who were infected with the deadly Ebola virus in Africa have been discharged from an Atlanta hospital, officials said Thursday. Read more...            

Eisai Submits EU Marketing Authorization for Anti-Epileptic

August 21, 2014 11:34 am | News | Comments

Eisai has submitted a Marketing Authorization Application to the European Commission for its first-in-class anti-epileptic drug (AED) Fycompa (perampanel) as an adjunctive treatment of primary generalized tonic-clonic seizures (PGTC). Read more...

FDA Approves GSK Asthma Drug

August 21, 2014 11:29 am | News | Comments

GlaxoSmithKline plc announced that the FDA has approved Arnuity Ellipta (fluticasone furoate inhalation powder), a once-daily inhaled corticosteroid (ICS) medicine for maintenance treatment of asthma as prophylactic therapy in patients aged 12 years and older. Read more...

Advertisement

Psoriasis Drug Fares Well in Late-Stage Trial

August 21, 2014 11:25 am | News | Comments

Drugmaker Eli Lilly and Co. said its potential psoriasis treatment fared better than both a fake drug and a competitor's product during late-stage testing on patients with the most common form of the skin disease and plans to submit the product, ixekizumab, to regulators in the first half of next year. Read more...

Researchers Restore Protein in Muscular Dystrophy

August 21, 2014 11:19 am | News | Comments

For the first time, a research team has succeeded in restoring a missing repair protein in skeletal muscle of three patients with muscular dystrophy carrying a dysferlin mutation who received a single systemic dose of a proteasome inhibitor. Read more...

Ebola: Slum Calm; Aid Worker Recovers

August 21, 2014 11:12 am | by Jonathan Paye-Layleh, Associated Press | News | Comments

Calm returned Thursday to a slum in the Liberian capital that was sealed off in the government's attempt to halt the spread of Ebola, a day after clashes erupted between residents and security forces, and in the United States, an aid worker who was infected in Liberia has recovered. Read more...

Novan’s Topical Treatment Shows Efficacy Against Drug-resistant Bugs

August 20, 2014 2:29 pm | News | Comments

Novan Therapeutics announced that the company’s Nitricil platform technology has been shown to be efficacious against several of the most multi-drug resistant pathogens plaguing civilian and military health care providers across the globe. Read more...

Novartis Licenses Candidate Compounds to TB Alliance

August 20, 2014 2:17 pm | News | Comments

Novartis has signed an exclusive worldwide licensing agreement with the Global Alliance for TB Drug Development (TB Alliance) for compounds to fight tuberculosis (TB). Read more...                    

FDA Approves New Drug for Gaucher's Disease

August 20, 2014 1:45 pm | News | Comments

The FDA approved a new capsule-based drug to treat Gaucher's disease. Regulators approved the new drug, Cerdelga, for patients with the Type 1 form of the rare genetic disorder. Read more...                 

Rating U.S. Drug Development Programs

August 20, 2014 11:10 am | by Chris Plaford, CFA, Chief Executive Officer, Claravant Analytics LLC | Articles | Comments

According to industry estimates, the majority of drugs in development will never make it to FDA approval. While a lack of efficacy is often a key factor, many clinical programs are derailed due to avoidable setbacks that can cause delays and significantly increase costs. Read more...

CEL-SCI Expands Head, Neck Cancer Trial in North America

August 20, 2014 10:47 am | News | Comments

CEL-SCI Corporation announced its Phase 3 Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine has added Centre Hospitalier Universitaire de Québec’s L’Hotel Dieu de Quebec to its growing number of clinical sites in North America. Read more...

Oramed Snags Oral Insulin Patent in Spain

August 20, 2014 10:40 am | News | Comments

Oramed Pharmaceuticals, a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced that the Intellectual Property Department of Spain has granted the company's patent for its invention, titled "Methods and Compositions for Oral Administrations of Proteins." Read more...

AstraZeneca, Mitsubishi Tanabe Collaborate in Diabetic Nephropathy

August 20, 2014 10:30 am | News | Comments

AstraZeneca and Mitsubishi Tanabe Pharma Corp. announced a three-year research collaboration in the area of diabetic nephropathy, which aims to leverage complementary strengths, expertise and assets to validate and progress novel research targets and molecules into clinical development. Read more...

Stemedica International Posts Alzheimer’s Stem Cell Data

August 20, 2014 10:24 am | News | Comments

Stemedica International, a Stemedica Cell Technologies subsidiary developing stem cell therapies for Alzheimer’s disease and dementia, revealed the first results of an intravenous administration of allogeneic, human, ischemia-tolerant mesenchymal stem cells in a pre-clinical animal model of Alzheimer’s disease. Read more...

Roche, Garvan Partner on Genomics Technologies

August 20, 2014 10:18 am | News | Comments

Roche and the Garvan Institute of Medical Research announced a collaboration to develop new technologies for targeted epigenomic analysis using DNA sequencing, bringing together the genomics expertise and infrastructure at the Garvan Institute and target enrichment products from Roche NimbleGen. Read more...

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading